Back to Journals » Open Access Journal of Contraception » Volume 1

Female pelvic actinomycosis and intrauterine contraceptive devices

Authors Perez-Lopez F, Tobajas JJ, Chedraui P

Published 10 May 2010 Volume 2010:1 Pages 35—38


Review by Single anonymous peer review

Peer reviewer comments 2

Download Article [PDF] 

Faustino R Pérez-López1,2, José J Tobajas1,3, Peter Chedraui4

1Department of Obstetrics and Gynecology, Facultad de Medicina, Universidad de Zaragoza; 2Hospital Clínico Lozano Blesa; 3Hospital Universitario Miguel Servet, Zaragoza, Spain; 4Enrique C. Sotomayor Obstetrics and Gynecology Hospital, Guayaquil, Ecuador

Abstract: Female genital Actinomyces infection is relatively rare, although strongly related to long-lasting intrauterine contraceptive device (IUD) application. An infective pathway has been postulated extending upward from the female perineum to the vagina and cervix. The traumatic effect of the device and a prior infection may contribute to the Actinomyces infection in the female genitalia. This disease is characterized by local swelling, suppuration, abscess formation, tissue fibrosis, tubal-ovarian mass and fistula formation. The infection spreads by contiguity often mimicking the characteristics of a malignant neoplastic process. Currently there is no consensus regarding diagnosis and screening tests, although there seems to be agreement in relation to IUD type, duration, and sexual behavior as major risk factors.

Keywords: contraception, intrauterine contraceptive device, pelvic actinomycosis, sexuality

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]